Litigation (3)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply … | |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply partner Pharmathen's Greece facility.
| |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner … | |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner facility Pharmathen manufacturing Lanreotide Injection.
| |||||||||||||||
Vodafone Idea provides clarification on news article regarding Supreme Court order on AGR dues. Supreme Court allows Union of India to … | |||||||||||||||
Vodafone Idea provides clarification on news article regarding Supreme Court order on AGR dues. Supreme Court allows Union of India to reconsider AGR matter given government's 49% equity stake and public interest involving 20 crore customers.
| |||||||||||||||